Wilson M, Bryan R T, Fried J A, Ware D A, Schantz P M, Pilcher J B, Tsang V C
Division of Parasitic Diseases, Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia 30333.
J Infect Dis. 1991 Nov;164(5):1007-9. doi: 10.1093/infdis/164.5.1007.
During the 3 years that the enzyme-linked immunoelectrotransfer blot (EITB) assay for the diagnosis of human cysticercosis has been in use at the Centers for Disease Control, 50 patients with both pathologically confirmed neurocysticercosis and computed tomographic (CT) or magnetic resonance imaging (MRI) scan results were identified. Of 32 patients with two or more lesions, 94% had detectable antibodies by EITB compared with 28% of 18 patients with single lesions. Patients with only calcified cysts (single or multiple) were less likely to have EITB-positive results than were those with noncalcified, enhancing lesions. Antibody was detectable more frequently in serum than in cerebrospinal fluid, regardless of the number or apparent condition of the cysts. These findings confirm that the EITB assay for cysticercosis antibodies is highly sensitive in patients with multiple, enhancing intracranial lesions but is less sensitive in patients with single lesions and in those with calcified lesions.
在疾病控制中心使用酶联免疫电转移印迹法（EITB）诊断人体囊尾蚴病的3年期间，共识别出50例经病理确诊为神经囊尾蚴病且有计算机断层扫描（CT）或磁共振成像（MRI）扫描结果的患者。在32例有两个或更多病灶的患者中，94%通过EITB检测到抗体，而18例有单个病灶的患者中这一比例为28%。仅有钙化囊肿（单个或多个）的患者EITB检测结果为阳性的可能性低于有非钙化、强化病灶的患者。无论囊肿数量或明显状况如何，血清中比脑脊液中更频繁地检测到抗体。这些发现证实，EITB检测囊尾蚴病抗体对有多个强化颅内病灶的患者高度敏感，但对有单个病灶的患者以及有钙化病灶的患者敏感性较低。
